Skip to content
2000
image of Muvalaplin: A Novel Oral Therapy for Targeted Reduction of Plasma Lipoprotein(a)

Abstract

Plasma lipoprotein(a) [Lp(a)] levels greater than 50 mg/dL are an independent risk factor for cardiovascular diseases, including heart failure, atherosclerosis, and aortic valve stenosis. Lp(a) exhibits proatherogenic properties by promoting vascular inflammation, thrombosis, and calcification. Several therapeutic agents specifically designed to reduce Lp(a) formation are currently under evaluation in clinical trials or regulatory review. Muvalaplin is notable as the first orally administered drug developed to lower plasma Lp(a) levels. This review evaluates the efficacy, safety, and tolerability of muvalaplin and compares its profile with other Lp(a)-lowering agents. A systematic literature search was conducted using the PubMed database for articles published between 2020 and 2025, with keywords, including muvalaplin, lipoprotein, and cardiovascular. Only original research, clinical trials, and review articles were included. Muvalaplin is an oral small-molecule inhibitor being studied as the first oral Lp(a)-lowering agent. In Phase I trials, daily administration of muvalaplin for 14 days reduced Lp(a) levels by up to 65%. In Phase II trials, 12 weeks of daily muvalaplin resulted in reductions of up to 86% in Lp(a) levels without significant safety or tolerability concerns. These findings suggest that muvalaplin could be a valuable therapeutic option for managing cardiovascular risk associated with elevated Lp(a). Notably, unlike other Lp(a)-lowering agents, muvalaplin did not cause skin-related adverse events at injection sites. Although the initial clinical data are promising, Phase III trials are required to establish long-term safety and determine whether reductions in plasma Lp(a) translate into meaningful reductions in cardiovascular events.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/chddt/10.2174/011871529X418596251201142137
2026-01-21
2026-02-28

  • From This Site

    /content/journals/chddt/10.2174/011871529X418596251201142137
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Duarte Lau F. Giugliano R.P. Lipoprotein(a) and its significance in cardiovascular disease. JAMA Cardiol. 2022 7 7 760 769 10.1001/jamacardio.2022.0987 35583875
    [Google Scholar]
  2. Nordestgaard B.G. Langsted A. Lipoprotein(a) and cardiovascular disease. Lancet 2024 404 10459 1255 1264 10.1016/S0140‑6736(24)01308‑4 39278229
    [Google Scholar]
  3. Vinci P. Di Girolamo F.G. Panizon E. Tosoni L.M. Cerrato C. Pellicori F. Altamura N. Pirulli A. Zaccari M. Biasinutto C. Roni C. Fiotti N. Schincariol P. Mangogna A. Biolo G. Lipoprotein(a) as a risk factor for cardiovascular diseases: Pathophysiology and treatment perspectives. Int. J. Environ. Res. Public Health 2023 20 18 6721 10.3390/ijerph20186721 37754581
    [Google Scholar]
  4. Reyes-Soffer G. Yeang C. Michos E.D. Boatwright W. Ballantyne C.M. High lipoprotein(a): Actionable strategies for risk assessment and mitigation. Am J. Prev Cardiol. 2024 18 100651 10.1016/j.ajpc.2024.100651 38646021
    [Google Scholar]
  5. Reyes-Soffer G. Ginsberg H.N. Berglund L. Duell P.B. Heffron S.P. Kamstrup P.R. Lloyd-Jones D.M. Marcovina S.M. Yeang C. Koschinsky M.L. Lipoprotein(a): A genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: A scientific statement from the American Heart Association. Arterioscler. Thromb. Vasc. Biol. 2022 42 1 e48 e60 10.1161/ATV.0000000000000147 34647487
    [Google Scholar]
  6. Fogacci F. Di Micoli V. Sabouret P. Giovannini M. Cicero A.F.G. Lifestyle and Lipoprotein(a) levels: Does a specific counseling make sense? J. Clin. Med. 2024 13 3 751 10.3390/jcm13030751 38337445
    [Google Scholar]
  7. Dimitriadis K. Kyriakoulis K.G. Pyrpyris N. Beneki E. Kamperidis V. Kollias A. Cenko E. Aznaouridis K. Aggeli K. Tsioufis K. Lipoprotein(a) and aortic stenosis: Practical insights. Nutr. Metab. Cardiovasc. Dis. 2025 ••• 104124 10.1016/j.numecd.2025.104124 40425406
    [Google Scholar]
  8. Arsenault B.J. Kamstrup P.R. Lipoprotein(a) and cardiovascular and valvular diseases: A genetic epidemiological perspective. Atherosclerosis 2022 349 7 16 10.1016/j.atherosclerosis.2022.04.015 35606078
    [Google Scholar]
  9. Brinck J. Littmann K. Hogling D.E. Widman L. Caidahl K. Eriksson M. Johnson J. Szummer K. Bäck M. Elevated lipoprotein(a) and progression of aortic stenosis measured by Doppler echocardiography: A population‐based cohort study. J. Intern. Med. 2025 298 1 46 48 10.1111/joim.20095 40309928
    [Google Scholar]
  10. Kronenberg F. Mora S. Stroes E.S.G. Ference B.A. Arsenault B.J. Berglund L. Dweck M.R. Koschinsky M. Lambert G. Mach F. McNeal C.J. Moriarty P.M. Natarajan P. Nordestgaard B.G. Parhofer K.G. Virani S.S. von Eckardstein A. Watts G.F. Stock J.K. Ray K.K. Tokgözoğlu L.S. Catapano A.L. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: A European Atherosclerosis Society consensus statement. Eur. Heart J. 2022 43 39 3925 3946 10.1093/eurheartj/ehac361 36036785
    [Google Scholar]
  11. Tsimikas S. Fazio S. Ferdinand K.C. Ginsberg H.N. Koschinsky M.L. Marcovina S.M. Moriarty P.M. Rader D.J. Remaley A.T. Reyes-Soffer G. Santos R.D. Thanassoulis G. Witztum J.L. Danthi S. Olive M. Liu L. NHLBI Working group recommendations to reduce lipoprotein(a)-Mediated risk of cardiovascular disease and aortic stenosis. J. Am. Coll. Cardiol. 2018 71 2 177 192 10.1016/j.jacc.2017.11.014 29325642
    [Google Scholar]
  12. Nicholls S.J. Therapeutic potential of Lipoprotein(a) inhibitors. Drugs 2024 84 6 637 643 10.1007/s40265‑024‑02046‑z 38849700
    [Google Scholar]
  13. Nicholls S.J. Nissen S.E. Fleming C. Urva S. Suico J. Berg P.H. Linnebjerg H. Ruotolo G. Turner P.K. Michael L.F. Muvalaplin, an oral small molecule inhibitor of lipoprotein(a) formation. JAMA 2023 330 11 1042 1053 10.1001/jama.2023.16503 37638695
    [Google Scholar]
  14. Diaz N. Perez C. Escribano A.M. Sanz G. Priego J. Lafuente C. Barberis M. Calle L. Espinosa J.F. Priest B.T. Zhang H.Y. Nosie A.K. Haas J.V. Cannady E. Borel A. Schultze A.E. Sauder J.M. Hendle J. Weichert K. Nicholls S.J. Michael L.F. Discovery of potent small-molecule inhibitors of lipoprotein(a) formation. Nature 2024 629 8013 945 950 10.1038/s41586‑024‑07387‑z 38720069
    [Google Scholar]
  15. Nicholls S.J. Ni W. Rhodes G.M. Nissen S.E. Navar A.M. Michael L.F. Haupt A. Krege J.H. Oral Muvalaplin for lowering of Lipoprotein(a). JAMA 2025 333 3 222 231 10.1001/jama.2024.24017 39556768
    [Google Scholar]
  16. McLean J.W. Tomlinson J.E. Kuang W.J. Eaton D.L. Chen E.Y. Fless G.M. Scanu A.M. Lawn R.M. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1987 330 6144 132 137 10.1038/330132a0 3670400
    [Google Scholar]
  17. Katsiki N. Vrablik M. Banach M. Gouni-Berthold I. Lp(a)-Lowering agents in development: A new era in tackling the burden of cardiovascular risk? Pharmaceuticals 2025 18 5 753 10.3390/ph18050753 40430570
    [Google Scholar]
  18. Sung D.E. Rhee E.J. Lee J.Y. Lee M.Y. Sung K.C. Elevated lipoprotein(a) is not linked to coronary artery calcification incidence or progression. Eur. J. Prev. Cardiol. 2025 32 9 746 755 10.1093/eurjpc/zwaf088 40179012
    [Google Scholar]
  19. Nicholls S.J. Nelson A.J. Current perspectives on Lp(a)-lowering therapies: Who may benefit? Kardiol. Pol. 2025 83 6 688 694 10.33963/v.phj.106327 40396911
    [Google Scholar]
  20. Hooper A.J. Fernando P.M.S. Burnett J.R. Potential of muvalaplin as a lipoprotein(a) inhibitor. Expert Opin. Investig. Drugs 2024 33 1 5 7 10.1080/13543784.2024.2302592 38186354
    [Google Scholar]
  21. Vuorio A. Kovanen P.T. Raal F. Promising results with the daily oral small molecule lipoprotein(a) inhibitor, muvalaplin, in high-risk cardiovascular patients with elevated lipoprotein(a) levels. Ann. Transl. Med. 2025 13 2 11 10.21037/atm‑25‑40 40438517
    [Google Scholar]
  22. Patel A.P. Wang M. Pirruccello J.P. Ellinor P.T. Ng K. Kathiresan S. Khera A.V. Lp(a) (Lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 2021 41 1 465 474 10.1161/ATVBAHA.120.315291 33115266
    [Google Scholar]
  23. ClinicalTrials.gove. Search Results. 2025 Available from: https://clinicaltrials.gov/search?intr=LY3473329
  24. Surma S. Zembala M.O. Okopień B. Banach M. Lipoprotein (a) and lipid-lowering treatment from the perspective of a cardiac surgeon. An impact on the prognosis in patients with aortic valve replacement and after heart transplantation. Int. J. Cardiol. Cardiovasc Risk Prev 2024 22 200297 10.1016/j.ijcrp.2024.200297 38962113
    [Google Scholar]
  25. Bhatia H.S. Dalal S. Ross E. Peripheral arterial disease associated with elevated lipoprotein(a): A review of the evidence and treatment approaches. Curr. Opin. Lipidol. 2025 36 5 238 250 10.1097/MOL.0000000000000999 40511686
    [Google Scholar]
  26. Thanigaimani S. Kumar M. Golledge J. Lipoprotein(a) and peripheral artery disease: Contemporary evidence and therapeutic advances. Curr. Opin. Lipidol. 2025 36 5 258 267 10.1097/MOL.0000000000000998 40396399
    [Google Scholar]
  27. Swearingen C.A. Sloan J.H. Rhodes G.M. Siegel R.W. Bivi N. Qian Y. Konrad R.J. Boffa M. Koschinsky M. Krege J. Ruotolo G. Nicholls S.J. Michael L.F. Wen Y. Measuring Lp(a) particles with a novel isoform-insensitive immunoassay illustrates efficacy of muvalaplin. J. Lipid Res. 2025 66 1 100723 10.1016/j.jlr.2024.100723 39647781
    [Google Scholar]
  28. Baragetti A. Da Dalt L. Norata G.D. New insights into the therapeutic options to lower lipoprotein(a). Eur. J. Clin. Invest. 2024 54 9 e14254 10.1111/eci.14254 38778431
    [Google Scholar]
  29. Sinha M. Maged R. Tarar P. Bandi V.V. Koneru H.M. Sarwar H. Efficacy of traditional anti-lipidemic drugs in lowering Lipoprotein(a) levels: A systematic review. Cureus 2024 16 9 e69824 10.7759/cureus.69824 39435209
    [Google Scholar]
  30. O’Donoghue M.L. Fazio S. Giugliano R.P. Stroes E.S.G. Kanevsky E. Gouni-Berthold I. Im, K.; Lira Pineda, A.; Wasserman, S.M.; Češka, R.; Ezhov, M.V.; Jukema, J.W.; Jensen, H.K.; Tokgözoğlu, S.L.; Mach, F.; Huber, K.; Sever, P.S.; Keech, A.C.; Pedersen, T.R.; Sabatine, M.S. Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk. Circulation 2019 139 12 1483 1492 10.1161/CIRCULATIONAHA.118.037184 30586750
    [Google Scholar]
  31. Bittner V.A. Szarek M. Aylward P.E. Bhatt D.L. Diaz R. Edelberg J.M. Fras Z. Goodman S.G. Halvorsen S. Hanotin C. Harrington R.A. Jukema J.W. Loizeau V. Moriarty P.M. Moryusef A. Pordy R. Roe M.T. Sinnaeve P. Tsimikas S. Vogel R. White H.D. Zahger D. Zeiher A.M. Steg P.G. Schwartz G.G. Effect of Alirocumab on Lipoprotein(a) and cardiovascular risk after acute coronary syndrome. J. Am. Coll. Cardiol. 2020 75 2 133 144 10.1016/j.jacc.2019.10.057 31948641
    [Google Scholar]
  32. Tsioulos G. Kounatidis D. Vallianou N.G. Poulaki A. Kotsi E. Christodoulatos G.S. Tsilingiris D. Karampela I. Skourtis A. Dalamaga M. Lipoprotein(a) and atherosclerotic cardiovascular disease: Where do we stand? Int. J. Mol. Sci. 2024 25 6 3537 10.3390/ijms25063537 38542510
    [Google Scholar]
  33. Sahebkar A. Reiner Ž. Simental-Mendía L.E. Ferretti G. Cicero A.F.G. Effect of extended-release niacin on plasma lipoprotein(a) levels: A systematic review and meta-analysis of randomized placebo-controlled trials. Metabolism 2016 65 11 1664 1678 10.1016/j.metabol.2016.08.007 27733255
    [Google Scholar]
  34. Ridker P.M. Lei L. Ray K.K. Ballantyne C.M. Bradwin G. Rifai N. Effects of bempedoic acid on CRP, IL-6, fibrinogen and lipoprotein(a) in patients with residual inflammatory risk: A secondary analysis of the CLEAR harmony trial. J. Clin. Lipidol. 2023 17 2 297 302 10.1016/j.jacl.2023.02.002 36813656
    [Google Scholar]
  35. Milosavljevic M.N. Stefanovic S.M. Pejcic A.V. Potential novel RNA-targeting agents for effective lipoprotein(a) lowering: A systematic assessment of the evidence from completed and ongoing developmental clinical trials. J. Cardiovasc. Pharmacol. 2023 82 1 1 12 10.1097/FJC.0000000000001429 37070852
    [Google Scholar]
  36. Bigazzi F. Sbrana F. Berretti D. Maria Grazia Z. Zambon S. Fabris A. Fonda M. Vigna G.B. D’Alessandri G. Passalacqua S. Dal Pino B. Pianelli M. Luciani R. Ripoli A. Rafanelli D. Manzato E. Cattin L. Sampietro T. Reduced incidence of cardiovascular events in hyper-Lp(a) patients on lipoprotein apheresis. The G.I.L.A. (Gruppo Interdisciplinare Aferesi Lipoproteica) pilot study. Transfus. Apheresis Sci. 2018 57 5 661 664 10.1016/j.transci.2018.07.015 30087087
    [Google Scholar]
  37. Anchouche K. Thanassoulis G. Lp(a): A rapidly evolving therapeutic landscape. Curr. Atheroscler. Rep. 2024 27 1 7 10.1007/s11883‑024‑01252‑0 39576403
    [Google Scholar]
  38. O’Donoghue M.L. Rosenson R.S. Gencer B. López J.A.G. Lepor N.E. Baum S.J. Stout E. Gaudet D. Knusel B. Kuder J.F. Ran X. Murphy S.A. Wang H. Wu Y. Kassahun H. Sabatine M.S. Small interfering RNA to reduce Lipoprotein(a) in cardiovascular disease. N. Engl. J. Med. 2022 387 20 1855 1864 10.1056/NEJMoa2211023 36342163
    [Google Scholar]
  39. Afzal Z. Hira S. Cao H. Emerging Lp(a)-lowering therapies: Is muvalaplin a potential breakthrough? Int. J. Cardiol. Cardiovasc Risk Prev 2024 21 200262 10.1016/j.ijcrp.2024.200262 39118982
    [Google Scholar]
  40. Kanbay M. Ozbek L. Guldan M. Yilmaz Z.Y. Ortiz A. Mallamaci F. Zoccali C. siRNA ‐based therapeutics for lipoprotein (a) lowering: A path toward precision cardiovascular medicine. Eur. J. Clin. Invest. 2025 55 9 e70079 10.1111/eci.70079 40407123
    [Google Scholar]
  41. Afzal Z. Cao H. Chaudhary M. Chigurupati H.D. Neppala S. Alruwaili W. Awad M. Sandesara D. Siddique M. Farman A. Zafrullah F. Gonuguntla K. Sattar Y. Elevated lipoprotein(a) levels: A crucial determinant of cardiovascular disease risk and target for emerging therapies. Curr. Probl. Cardiol. 2024 49 8 102586 10.1016/j.cpcardiol.2024.102586 38653440
    [Google Scholar]
  42. Tsimikas S. Karwatowska-Prokopczuk E. Gouni-Berthold I. Tardif J.C. Baum S.J. Steinhagen-Thiessen E. Shapiro M.D. Stroes E.S. Moriarty P.M. Nordestgaard B.G. Xia S. Guerriero J. Viney N.J. O’Dea L. Witztum J.L. Lipoprotein(a) reduction in persons with cardiovascular disease. N. Engl. J. Med. 2020 382 3 244 255 10.1056/NEJMoa1905239 31893580
    [Google Scholar]
  43. Assessing the impact of Lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients with CVD (Lp(a)HORIZON). NCT04023552. 2025 Available from: https://clinicaltrials.gov/study/NCT04023552
  44. Nissen S.E. Ni W. Shen X. Wang Q. Navar A.M. Nicholls S.J. Wolski K. Michael L. Haupt A. Krege J.H. Lepodisiran: A long-duration small interfering RNA targeting Lipoprotein(a). N. Engl. J. Med. 2025 392 17 1673 1683 10.1056/NEJMoa2415818 40162643
    [Google Scholar]
  45. Nissen S.E. Wolski K. Balog C. Swerdlow D.I. Scrimgeour A.C. Rambaran C. Wilson R.J. Boyce M. Ray K.K. Cho L. Watts G.F. Koren M. Turner T. Stroes E.S. Melgaard C. Campion G.V. Single ascending dose study of a short interfering RNA targeting Lipoprotein(a) production in individuals with elevated plasma lipoprotein(a) levels. JAMA 2022 327 17 1679 1687 10.1001/jama.2022.5050 35368052
    [Google Scholar]
  46. Nissen S.E. Wang Q. Nicholls S.J. Navar A.M. Ray K.K. Schwartz G.G. Szarek M. Stroes E.S.G. Troquay R. Dorresteijn J.A.N. Fok H. Rider D.A. Romano S. Wolski K. Rambaran C. Zerlasiran: A small-interfering RNA targeting lipoprotein(a). JAMA 2024 332 23 1992 2002 10.1001/jama.2024.21957 39556769
    [Google Scholar]
/content/journals/chddt/10.2174/011871529X418596251201142137
Loading
Muvalaplin: A Novel Oral Therapy for Targeted Reduction of Plasma Lipoprotein(a)
Bentham Science Publishers ; https://doi.org/10.2174/011871529X418596251201142137
/content/journals/chddt/10.2174/011871529X418596251201142137
/content/journals/chddt/10.2174/011871529X418596251201142137
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: statin ; pelacarsen ; cardiovascular events ; olpasiran ; muvalaplin ; Lipid disorders ; lipoprotein(a) ; apolipoprotein

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test